Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Cutaneous Sclerosis”

81 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 81 results

Early research (Phase 1)Study completedNCT01031901
What this trial is testing

Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)

Who this might be right for
Tuberous SclerosisNeurofibromatosesAngiofibroma+1 more
The University of Texas Health Science Center, Houston 52
Not applicableUnknownNCT03674346
What this trial is testing

Efficacy of Hypnoanalgesia by a Radiologist Technologist in Children With Cutaneous Angioma Treated With Sclerosis in Interventional Radiology

Who this might be right for
Angioma
Hospices Civils de Lyon 138
Early research (Phase 1)Study completedNCT02426229
What this trial is testing

Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma

Who this might be right for
SclerodermaInterstitial Lung Disease
Medical University of South Carolina 15
Large-scale testing (Phase 3)Active Not RecruitingNCT05925803
What this trial is testing

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

Who this might be right for
Systemic SclerosisScleroderma
AstraZeneca 314
Testing effectiveness (Phase 2)Ended earlyNCT03919799
What this trial is testing

KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis

Who this might be right for
System; SclerosisDiffuse Cutaneous Systemic Sclerosis
Kadmon, a Sanofi Company 36
Testing effectiveness (Phase 2)WithdrawnNCT02588625
What this trial is testing

A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Who this might be right for
Scleroderma
Bristol-Myers Squibb
Testing effectiveness (Phase 2)Looking for participantsNCT03844061
What this trial is testing

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Who this might be right for
Systemic Sclerosis
Hospital for Special Surgery, New York 30
Testing effectiveness (Phase 2)Study completedNCT02161406
What this trial is testing

Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis

Who this might be right for
Diffuse Cutaneous Systemic Sclerosis
Dinesh Khanna, MD, MS 88
Testing effectiveness (Phase 2)Study completedNCT03041025
What this trial is testing

Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis

Who this might be right for
Scleroderma, Systemic
GlaxoSmithKline 35
Not applicableStudy completedNCT02339441
What this trial is testing

Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis

Who this might be right for
Early Diffuse Cutaneous Systemic Sclerosis
University of Manchester 320
Post-approval studies (Phase 4)Study completedNCT07472166
What this trial is testing

Efficacy of Tofacitinib on Skin Thickening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate

Who this might be right for
Scleroderma, Systemic
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh 34
Large-scale testing (Phase 3)Looking for participantsNCT06716606
What this trial is testing

Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)

Who this might be right for
Connective Tissue Diseases
GlaxoSmithKline 514
Post-approval studies (Phase 4)Study completedNCT04464434
What this trial is testing

Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis

Who this might be right for
Systemic SclerosisSystemic Scleroses, DiffuseScleroderma+5 more
UMC Utrecht 60
Early research (Phase 1)Study completedNCT00656825
What this trial is testing

Tolerability and Bioavailability of the P144 Peptide Inhibitor of TGF-β1 After Topical Administration in Healthy Volunteers

Who this might be right for
Healthy
ISDIN 36
Not applicableWithdrawnNCT02531009
What this trial is testing

Systemic Sclerosis Clinical and Biomarker Study

Who this might be right for
HealthySystemic Sclerosis
Biogen
Testing effectiveness (Phase 2)Study completedNCT01670565
What this trial is testing

Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Who this might be right for
Systemic Sclerosis
Hospital for Special Surgery, New York 20
Not applicableUnknownNCT05168215
What this trial is testing

Effectiveness of Bosentan Therapy in Patients With Systemic scleRosis and Progressive Digital ulcEr Disease.

Who this might be right for
SclerodermaDigital UlcerAutoimmune Diseases+2 more
Elpen Pharmaceutical Co. Inc. 300
Testing effectiveness (Phase 2)Study completedNCT00479934
What this trial is testing

Efficacy and Safety of Imatinib in Scleroderma

Who this might be right for
Scleroderma, LocalizedScleroderma, Systemic
University Hospital, Bordeaux 28
Testing effectiveness (Phase 2)UnknownNCT00769028
What this trial is testing

AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis

Who this might be right for
Systemic Sclerosis
Daval International Limited 20
Testing effectiveness (Phase 2)UnknownNCT04927390
What this trial is testing

Mycophenolate in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot)

Who this might be right for
Systemic SclerosisLimited Cutaneous Systemic Sclerosis
University College, London 120
Next Page